Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 57

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 57
---
.

Corporate Information

Our principal executive offices are located at 10500 University Center Drive, Suite 110, Tampa, Florida 33612. Our telephone number is (813) 875-6600. Our principal website address is www.tuhurabio.com. The information contained on, or that can be accessed through, our website is deemed not to be incorporated in this prospectus supplement or to be part
of this prospectus supplement. You should not consider information contained on its website to be part of this prospectus supplement.

S-4

THE OFFERING The following summary contains basic information about this offering. The summary is not intended to be complete. You should read the full text and more specific details contained elsewhere in this prospectus supplement.

| Issuer | TuHURA Biosciences, Inc. |

| Common Stock offered by us | Shares of our Common Stock having an aggregate offering price of up to $50,000,000. |

| Common Stock to be outstanding after this 
 offering(1)                               | Up to 71,419,678 shares, after giving effect to the assumed sale of 20,161,290 shares of our Common Stock, at a price of $2.48 per share, which was the closing price of our Common Stock on the Nasdaq Capital Market on October 30, 2025. 
 The actual number of shares issued will vary depending on the sales price under this offering.                                                                                                                                              |

| Form of offering | “At the market offering” of our Common Stock that may be made from time to time through or to the Sales Agent, as agent or principal. See “Plan of Distribution” on page S-11 of this 
 prospectus supplement.                                                                                                                                                                |

| Nasdaq Capital Market symbol | HURA |

| Use of proceeds | We currently intend to use the net proceeds from this offering for working capital and general corporate purposes. See “Use of Proceeds” on page S-9 of this prospectus supplement. |

| Risk factors | See “Risk Factors” on page S-4 and the other information included or incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of certain factors 
 you should carefully consider before deciding to invest in shares of our Common Stock.                                                                                                           |

| (1) | The number of shares of Common Stock to be outstanding after the offering is based on 51,258,388 shares of 
 Common Stock outstanding at October 30, 2025, excludes the following as of October